Additionally, Aurora kinase inhibitor CCT137690 has also shown preclinical efficacy, downregulating MYCN, upregulating p53, and inhibiting neuroblastoma tumor growth in vitro and in vivo. The gene discussed is MYCN; the disease is neoplasm.